Prestige BioPharma Limited (950210.KS)

KRW 15050.0

(-4.57%)

Total Liabilities Summary of Prestige BioPharma Limited

  • Prestige BioPharma Limited's latest annual total liabilities in 2023 was 196.21 Billion KRW , up 0.44% from previous year.
  • Prestige BioPharma Limited's latest quarterly total liabilities in 2023 Q3 was 194.33 Billion KRW , up 2.01% from previous quarter.
  • Prestige BioPharma Limited reported annual total liabilities of 195.36 Billion KRW in 2022, up 179.58% from previous year.
  • Prestige BioPharma Limited reported annual total liabilities of 69.87 Billion KRW in 2021, up 139.26% from previous year.
  • Prestige BioPharma Limited reported quarterly total liabilities of 200.69 Billion KRW for 2023 Q1, up 2.73% from previous quarter.
  • Prestige BioPharma Limited reported quarterly total liabilities of 194.33 Billion KRW for 2023 Q3, up 2.01% from previous quarter.

Annual Total Liabilities Chart of Prestige BioPharma Limited (2023 - 2017)

Historical Annual Total Liabilities of Prestige BioPharma Limited (2023 - 2017)

Year Total Liabilities Total Liabilities Growth
2023 196.21 Billion KRW 0.44%
2022 195.36 Billion KRW 179.58%
2021 69.87 Billion KRW 139.26%
2020 29.2 Billion KRW 30.98%
2019 22.29 Billion KRW -50.16%
2018 44.73 Billion KRW 237.37%
2017 13.26 Billion KRW 0.0%

Peer Total Liabilities Comparison of Prestige BioPharma Limited

Name Total Liabilities Total Liabilities Difference
ORIENT BIO Inc. 11.89 Billion KRW -1550.032%
Green Cross Holdings Corporation 1856.16 Billion KRW 89.429%
Green Cross Holdings Corporation 1103.45 Billion KRW 82.218%
Pharmicell Co., Ltd. 18.79 Billion KRW -944.03%
Green Cross Corporation 1103.45 Billion KRW 82.218%
GeneOne Life Science, Inc. 39.51 Billion KRW -396.523%
Celltrion, Inc. 2791.73 Billion KRW 92.971%
Samsung Biologics Co.,Ltd. 6215.7 Billion KRW 96.843%
SK bioscience Co.,Ltd. 148.58 Billion KRW -32.059%
SK Biopharmaceuticals Co., Ltd. 402.21 Billion KRW 51.216%